New study offers reassurance for patients with some cancer-linked genes
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-Apr-2025 09:08 ET (24-Apr-2025 13:08 GMT/UTC)
As more people receive genetic testing after a cancer diagnosis, newer variants have been identified that increase risk of developing cancer. A new study led by the University of Michigan Rogel Cancer Center finds that patients with three of these variants face no extra risk of dying from their cancer.
A new study in JAMA Pediatrics found that the spike in gun death rates during the first two years of the pandemic disproportionately affected adolescents ages 10-16, as well as adults over 30 years old. These increases lowered the peak risk of being a victim of a fatal shooting from 21 years old to 19 years old. The study also found that as adult gun death rates returned to pre-COVID levels in 2022 and 2023, gun homicide rates continued increasing for the 10-16 adolescent age group, doubling pre-pandemic rates.
In an effort to find new treatments for castrate-resistant prostate cancer, a TTUHSC research team led by Srinivas Nandana, Ph.D., and Manisha Tripathi, Ph.D., recently completed a study focused on uncovering the molecular and signaling mechanisms that drive the progression of advanced prostate cancer. Their study (“A TBX2-Driven Signaling Switch from Androgen Receptor to Glucocorticoid Receptor Confers Therapeutic Resistance in Prostate Cancer”), published by Oncogene, emphasized overcoming resistance to androgen receptor signaling inhibitors.
UChicago researchers develop a new technology to create a spatial map of gene expression for an entire organism.